Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics develops antibody treatments for psoriasis and other immune and inflammatory conditions. It last closed at $96.32 on Nov 17, down 2.94% on the day. The average 12-month price target from 2 analysts is $182.50 (+89.5% from the last close), with a high of $200.00 and a low of $165.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in ORKA, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints totaling $2.2M, the largest $1.1M.
Key Stats
Last 12 monthsNot reported for this period.
From ORKA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on ORKA in the past 90 days. The average target is $182.50, with a high of $200.00 and a low of $165.00, compared with the last close of $96.32.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Guggenheim | Reiterated | Buy | $200 |
| Oct 27 | Wedbush | Reiterated | Buy | $165 |
| Aug 11 | Guggenheim | Reiterated | Buy | $200 |
| Aug 11 | Wedbush | Reiterated | Buy | $165 |
| Aug 3 | HC Wainwright & Co. | Reiterated | Buy | $120 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 24% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 51). The nearest support is the swing low (Aug 10) at $95.50, and the nearest resistance the swing high (Sep 8) at $96.44.
| RSI (14) | 50.91 | Middle of its range | Neutral |
| MACD | 4.35 | Below its signal line | Bearish |
| Stochastic | 35.4 | Middle of its range | Neutral |
| ADX (14) | 32.5 | Trending up | |
| Williams %R | -88.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | 5.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −3.2% | Change over 10 sessions | Bearish |
| ATR (14) | $5.85 | Typical daily range, 6.1% of price |
| RSI (14) | 57.74 | Middle of its range | Neutral |
| MACD | 7.50 | Below its signal line | Bearish |
| Stochastic | 68.9 | Middle of its range | Neutral |
| ADX (14) | 36.9 | Trending up | |
| Williams %R | -42.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 67.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +4.3% | Change over 10 sessions | Bullish |
| ATR (14) | $10.96 | Typical daily range, 11.4% of price |
What happened before
See how ORKA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ORKA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ORKA in the last 90 days.
Dark Pool
30DORKA Institutional Ownership
Full report →- ▲156 buying vs 113 selling
- ▲Held by funds +3.8 pts
- ●Funds holding +2
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 259 | 257 | +0.8% |
| In funds' top 10 | 7 | 14 | −50.0% |
| Held by funds | 113.2% | 109.3% | +3.8 pts |
| New / increased | 38 / 118 | 96 / 94 | −17.9% |
| Reduced / sold out | 77 / 36 | 47 / 27 | +52.7% |
| Put/call ratio | 1.46 | 1.00 | +45.9% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORKA is in one of them and how their past ORKA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ORKA in an article yet. Here's the latest on the wider market.
About Oruka Therapeutics
Oruka Therapeutics is a biopharmaceutical company based in Menlo Park, California. It is developing antibody treatments for psoriasis, a chronic skin disease, along with other immune and inflammatory conditions such as hidradenitis suppurativa and psoriatic arthritis. Its lead candidates are designed to act on IL-23 and IL-17 signaling. The company's products are still in clinical trials and not yet approved, and it aims to serve people living with these chronic skin and joint conditions.
- Headquarters
- Menlo Park, CA


